Adapted from

Endo Pharmaceuticals

Endo Pharmaceuticals began in 1920 as a family-owned business in New York City. In 1969, it was acquired by the DuPont Company, which formed a joint venture with Merck & Co. in 1990. A new era in Endo’s history began in 1997, when Endo was formed as an independent company through a management buyout from DuPont Merck.

“Today, we’re working in pain management, urology, endocrinology and oncology. We’re evaluating new drug delivery technologies to create innovative new medicines,” said Blaine Davis, vice president of Corporate Affairs. “We’re empowering our commercial team to work with physicians and payers to become real partners in medical care, not just suppliers. These are exciting changes that move us closer to our goal of becoming the premier specialty company.” Net sales for 2008 were $1.26 billion.

Flagship Products

Endo’s top-selling product is LIDODERM^® (lidocaine patch 5%), a branded topical skin patch that was the first topical treatment approved by the FDA to help relieve the pain of postherpetic neuralgia, also referred to as post-shingles pain. Net sales of LIDODERM were $765.1 million in 2008.

Other Pain Products

• Voltaren^® Gel (diclofenac sodium topical gel) 1% is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the hands and knees. Voltaren Gel has not been evaluated for use on the spine, hip or shoulder.
  
• OPANA^® ER (oxymorphone HCl) extended-release tablets CII is an extended-release oral form of oxymorphone that has been studied in a wide range of chronic pain conditions, including osteoarthritis, cancer pain and low back pain. OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time and is not intended to be used on an as-needed basis.
  
• OPANA^® (oxymorphone HCl) tablets CII, an immediate-release formulation of oxymorphone, is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate.
• PERCOCET^® (oxycodone and acetaminophen tablets, USP) is indicated for the relief of moderate to moderately severe pain.
• FROVA^® (frovatriptan) is indicated for the treatment of acute migraine headaches in adults.
• Endo also markets selected generic products, including ENDOCET^® and morphine sulfate ER.

Urology, Endocrinology and Oncology Products

SANCTURA XR^TM (trospium chloride extended-release capsules), a once-daily formulation of SANCTURA^®, is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. Endo currently co-promotes SANCTURA XR in the United States with its marketing partner, Allergan, Inc.

SUPPRELIN^® LA (histrelin acetate) is a 12-month hydrogel implant containing the medicine histrelin, a gonadotropin-releasing hormone agonist. SUPPRELIN LA is indicated for the treatment of children with central precocious puberty.

VALSTAR^™ (valrubicin) is a sterile solution for intravesical instillation of valrubicin and is the only product currently approved by the FDA for therapy of bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ of the urinary bladder. VALSTAR is used in patients with BCG-refractory bladder cancer who are not candidates for bladder removal (cystectomy).

VANTAS^® (histrelin implant) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone agonist, for the palliative treatment of advanced prostate cancer.

In the Pipeline

Our pipeline portfolio contains products and product candidates that have differentiating features for multiple therapeutic areas, including pain, oncology, urology and endocrinology.

This corporate profile was reviewed and approved by Endo Pharmaceuticals.

Close